Long-chain PUFA in granulocytes, mononuclear cells, and RBC in patients with cystic fibrosis: Relation to liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 55, Issue 1, 2012, Pages 76-81

  Jørgensen, Marianne H ^a   Ott, Peter ^b   Michaelsen, Kim F ^c   Porsgaard, Trine ^d   Jensen, Fleming ^a   Lanng, Susanne ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

cystic fibrosis; hepatic transit time; liver; long chain polyunsaturated fatty acids; nutrition

Indexed keywords

FISH OIL; N 3 LONG CHAIN POLYUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CELL LINE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; ERYTHROCYTE; FEMALE; FOOD INTAKE; FORCED EXPIRATORY VOLUME; GRANULOCYTE; HEMATOLOGY; HUMAN; LIPID COMPOSITION; LIVER DISEASE; MALE; MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANIMALS; ARACHIDONIC ACID; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DIET; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; FISHES; GRANULOCYTES; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER DISEASES; MALE; OLEIC ACID; QUESTIONNAIRES; YOUNG ADULT;

PSEUDOMONAS AERUGINOSA;

EID: 84862312994     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318249438c     Document Type: Article

References (37)

1. Dodge JA, Morison S, Lewis PA, et al. Cystic fibrosis in the United Kingdom, 1968-1988: inciDence, population and survival. Paediatr Perinat Epidemiol 1993;7:157-66.
2. Koch C, Cuppens H, Rainisio M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001;31:1-12.
3. Schwartz M, Brandt NJ, Koch C, et al. Genetic analysis of cystic fibrosis in Denmark. Implications for genetic counselling, carrier diagnosis and prenatal diagnosis. Acta Paediatr 1992;81:522-6.
4. Lloyd-Still JD, Johnson SB, Holman RT. Essential fatty acid status and fluidity of plasma phospholipids in cystic fibrosis infants. Am J Clin Nutr 1991;54:1029-35.
5. Lloyd-Still JD, Bibus DM, Powers CA, et al. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr 1996;85:1426-32.
6. Henderson WR Jr, Astley SJ, McCready MM, et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr 1994;124:400-8.
7. Roulet M, Frascarolo P, Rappaz I, et al. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997;156:952-6.
8. Benabdeslam H, Garcia I, Bellon G, et al. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. Am J Clin Nutr 1998;67:912-8.
9. Clandinin MT, Zuberbuhler P, Brown NE, et al. Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients. Am J Clin Nutr 1995;62:1268-75.
10. Strandvik B, Gronowitz E, Enlund F, et al. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001; 139:650-5.
11. Coste TC, Deumer G, Reychler G, et al. Influence of pancreatic status and sex on polyunsaturated fatty acid profiles in cystic fibrosis. Clin Chem 2008;54:388-95.
12. Cawood AL, Carroll MP,Wootton SA, et al. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr Opin Clin Nutr Metab Care 2005;8:153-9.
13. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of inciDent atrial fibrillation. Circulation 2004;110:368-73.
14. Milte CM, Coates AM, Buckley JD, et al. Dose-depenDent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels. Br J Nutr 2008;99:1083-8.
15. Welch AA, Shakya-Shrestha S, Lentjes MA, et al. Dietary intake and status of n-3 polyunsaturated fatty acids in a population of fish-eating and non-fish-eating meat-eaters, vegetarians, and vegans and the product-precursor ratio [corrected] of alpha-linolenic acid to long-chain n-3 polyunsaturated fatty acids: results from the EPIC-Norfolk cohort. Am J Clin Nutr 2010;92:1040-51.
16. Freedman SD, Katz MH, Parker EM, et al. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci U S A 1999;96:13995-4000.
17. Freedman SD, Blanco PG, Zaman MM, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-9.
18. Cabre E, Gassull MA. Polyunsaturated fatty acid deficiency in liver diseases: pathophysiological and clinical significance. Nutrition 1996; 12:542-8.
19. Clemmesen JO, Hoy CE, Jeppesen PB, et al. Plasma phospholipid fatty acid pattern in severe liver disease. J Hepatol 2000;32:481-7.
20. Socha P, Koletzko B, Pawlowska J, et al. Essential fatty acid status in children with cholestasis, in relation to serum bilirubin concentration. J Pediatr 1997;131:700-6.
21. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991;66:698-701.
22. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on inciDence, risk factors, and outcome. Hepatology 2002;36:1374-82.
23. Colombo C, Battezzati PM, Strazzabosco M, et al. Liver and biliary problems in cystic fibrosis. Semin Liver Dis 1998;18:227-35.
24. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
25. Williams SG, Evanson JE, Barrett N, et al. An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis. J Hepatol 1995; 22:513-21.
26. Williams SM, Goodman R, Thomson A, et al. Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol 2002;57:365-70.
27. Colombo C, Crosignani A, Battezzati PM, et al. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease. J Hepatol 1999;31:672-7.
28. Lewindon PJ, Shepherd RW, Walsh MJ, et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy 2. Hepatology 2011;53:193-201.
29. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226:497-509.
30. Porsgaard T, Xu X, Gottsche J, et al. Differences in the intramolecular structure of structured oils do not affect pancreatic lipase activity in vitro or the absorption by rats of (n-3) fatty acids. J Nutr 2005;135:1705-11.
31. Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999;353:1579-83.
32. Freedman SD, Sullivan BPO, Martinez-Clark P, et al. An abnormality in AA/DHA metabolism is present in cftr-regulated tissues from CF patients. Pediatr Pulmonol 2000;20:158-9.
33. Jørgensen MH, Hernell O, Hughes E, et al. Is there a relation between docosahexaenoic acid concentration in mothers' milk and visual development in term infants? J Pediatr Gastroenterol Nutr 2001; 32:293-6.
34. Andersson C, Al-Turkmani MR, Savaille JE, et al. Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism. J Lipid Res 2008;49: 1692-700.
35. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S-19S.
36. Courtney JM, Ennis M, Elborn JS. Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros 2004;3:223-31.
37. Carlstedt-Duke J, Bronnegard M, Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci U S A 1986;83:9202-6.